A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

NCT03396211 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Apatinib
DRUG: Nivolumab

Sponsor

Elevar Therapeutics